INTERNATIONAL PATENT: ALEXION PHARMACEUTICALS, INC. FILES APPLICATION FOR "BIOMARKERS FOR MONITORING EFFECTIVE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH COMPLEMENT COMPONENT C5 INHIBITORS"

GENEVA, Oct. 28 -- ALEXION PHARMACEUTICALS, INC. (121 Seaport Blvd.Boston, MA 02210) filed a patent application (PCT/US2025/023106) for "BIOMARKERS FOR MONITORING EFFECTIVE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH COMPLEMENT COMPONENT C5 INHIBITORS" on Apr 04, 2025. With publication no. WO/2025/221479, the details related to the patent application was published on Oct 23, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): BOU-CHAHINE, Ruba, Deeb (121 Seaport Blvd.Boston, MA 02210)

Abstract: The disclosure provides biomarker proteins, a change in the concentration of whi...